Application of New McDonald MS Criteria Uncovers Portion of Atypical Individuals Potentially Eligible for Disease-Modifying Treatment

In the CAVS-MS study, 19% of participants with atypical or radiological-only presentations met the 2024 McDonald Criteria for MS, enabling earlier treatment initiation.:

Source: Neurology Read More

Previous PostComorbidity Burden Is Associated With Increased Adverse Events, DMT Discontinuation in MS Clinical Trials
Next PostImproved GFAP Levels With Ozanimod Linked to Slower Relapsing MS Progression

Application of New McDonald MS Criteria Uncovers Portion of Atypical Individuals Potentially Eligible for Disease-Modifying Treatment

Previous PostComorbidity Burden Is Associated With Increased Adverse Events, DMT Discontinuation in MS Clinical Trials

Next PostImproved GFAP Levels With Ozanimod Linked to Slower Relapsing MS Progression

Related Posts

<![CDATA[Once-Daily Alixorexton Improves Cognition, Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1 Study]]>

<![CDATA[NMOSD Associated With Escalation to Rituximab, Elecsys NfL Test Receives European Approval, Neurology by the Numbers]]>

<![CDATA[GLP-1 Receptor Agonists Show Translational Potential in Alzheimer Disease Despite Mixed Study Results]]>

Categories